vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $17.3M, roughly 1.1× Valens Semiconductor Ltd.). SCYNEXIS INC runs the higher net margin — 65.7% vs -42.2%, a 108.0% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 8.1%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
SCYX vs VLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $17.3M |
| Net Profit | $12.3M | $-7.3M |
| Gross Margin | — | 63.0% |
| Operating Margin | 56.3% | -46.4% |
| Net Margin | 65.7% | -42.2% |
| Revenue YoY | 1808.5% | 8.1% |
| Net Profit YoY | 376.5% | 29.3% |
| EPS (diluted) | $0.25 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | — | ||
| Q3 25 | $334.0K | $17.3M | ||
| Q2 25 | $1.4M | $17.1M | ||
| Q1 25 | $257.0K | $16.8M | ||
| Q4 24 | $977.0K | — | ||
| Q3 24 | $660.0K | $16.0M | ||
| Q2 24 | $736.0K | $13.6M | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $12.3M | — | ||
| Q3 25 | $-8.6M | $-7.3M | ||
| Q2 25 | $-6.9M | $-7.2M | ||
| Q1 25 | $-5.4M | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | $-10.4M | ||
| Q2 24 | $-14.5M | $-8.9M | ||
| Q1 24 | $411.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 63.0% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | — |
| Q4 25 | 56.3% | — | ||
| Q3 25 | -2516.5% | -46.4% | ||
| Q2 25 | -701.0% | -43.3% | ||
| Q1 25 | -3350.2% | -56.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1563.6% | -76.3% | ||
| Q2 24 | -1255.0% | -69.2% | ||
| Q1 24 | -692.5% | — |
| Q4 25 | 65.7% | — | ||
| Q3 25 | -2572.2% | -42.2% | ||
| Q2 25 | -504.8% | -42.1% | ||
| Q1 25 | -2097.7% | -49.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | -64.6% | ||
| Q2 24 | -1964.4% | -65.2% | ||
| Q1 24 | 29.9% | — |
| Q4 25 | $0.25 | — | ||
| Q3 25 | $-0.17 | $-0.07 | ||
| Q2 25 | $-0.14 | $-0.07 | ||
| Q1 25 | $-0.11 | $-0.08 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.06 | $-0.10 | ||
| Q2 24 | $-0.30 | $-0.08 | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $93.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $108.8M |
| Total Assets | $59.0M | $136.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | — | ||
| Q3 25 | $37.9M | $93.5M | ||
| Q2 25 | $44.8M | $102.7M | ||
| Q1 25 | $40.6M | $112.5M | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $68.8M | $133.1M | ||
| Q2 24 | $73.0M | $105.9M | ||
| Q1 24 | $80.2M | — |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $108.8M | ||
| Q2 25 | $44.5M | $116.5M | ||
| Q1 25 | $50.5M | $128.6M | ||
| Q4 24 | $55.1M | — | ||
| Q3 24 | $58.5M | $147.0M | ||
| Q2 24 | $60.4M | $153.5M | ||
| Q1 24 | $74.1M | — |
| Q4 25 | $59.0M | — | ||
| Q3 25 | $51.1M | $136.7M | ||
| Q2 25 | $60.7M | $144.8M | ||
| Q1 25 | $67.9M | $154.6M | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $99.0M | $171.9M | ||
| Q2 24 | $107.8M | $175.8M | ||
| Q1 24 | $118.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-4.7M |
| Free Cash FlowOCF − Capex | — | $-4.9M |
| FCF MarginFCF / Revenue | — | -28.5% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | — | ||
| Q3 25 | $-8.7M | $-4.7M | ||
| Q2 25 | $-7.5M | $-211.0K | ||
| Q1 25 | $-7.5M | $-7.6M | ||
| Q4 24 | $-24.0M | — | ||
| Q3 24 | $765.0K | $3.0M | ||
| Q2 24 | $-10.9M | $-225.0K | ||
| Q1 24 | $-4.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.9M | ||
| Q2 25 | — | $-330.0K | ||
| Q1 25 | — | $-8.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $-460.0K | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.5% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | — | -47.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | -3.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | — |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
VLN
Segment breakdown not available.
